Bruce Wesson

Bruce F. Wesson is a co-founder of Galen Partners, a healthcare-dedicated private equity firm founded in 1990 by the three-person team of William R. Grant, John Wilkerson, and Bruce Wesson. He formally joined the firm in 1991 and served as a Partner of Galen Associates and General Partner of the Galen Partners funds (including Galen Partners III, L.P.) from January 1991 until June 30, 2011, when he transitioned to his current role as Founding Partner Emeritus and Senior Advisor.

Before Galen, Wesson spent more than 23 years at Smith Barney, where he was a Senior Vice President and Managing Director in the Corporate Finance Division. In that role he directed the Major Account Group, served as Senior Managing Director in charge of the East Coast region, and chaired the firm's Valuation and Opinion Committee for Corporate Finance. That long investment-banking background — spanning capital raising, M&A, and fairness opinions — informed Galen's approach of pairing financial discipline with deep healthcare sector specialization.

Wesson earned a B.A. from Colgate University and an M.B.A. from Columbia University's Graduate School of Business. He has served extensively as a director and board member of Galen portfolio and public healthcare companies, including MedAssets (Vice Chairman), Derma Sciences, Acura Pharmaceuticals, Nautilus Neurosciences, Essential Group, and TPS, and has held a board seat at Chemtura Corporation. Outside of investing, he was a trustee of Colgate University for nine years, served as President of Colgate's Alumni Corporation Board of Directors, and is Chairman of the Board of the Overlook Hospital Foundation.

• Invests exclusively in healthcare, spanning medical devices and therapeutic devices, diagnostics, specialty pharmaceuticals, capital equipment, specialty supplies distribution, consumer-driven and home healthcare, and technology-enabled healthcare services.
• Galen positions itself as a specialist healthcare investor, with a team citing "over 70 years of combined healthcare industry and investment expertise" and supplementing capital with operating "Special Investment Partners" who have built healthcare companies.
• Historically a growth / expansion-stage private equity investor rather than a pure seed fund — backing companies with products, revenue, or clear commercialization paths and then adding board-level operational and financial guidance.
• Values hands-on governance: Wesson personally took board seats (often as chairman or vice chairman) at portfolio and public companies, reflecting a preference for active, value-added involvement rather than passive checks.